TTC18 Activators encompass a series of chemical compounds that indirectly enhance the functional activity of TTC18 through different signaling pathways and cellular processes. Forskolin, by increasing cAMP levels, could activate PKA, which may phosphorylate TTC18 or related regulatory proteins, thus enhancing TTC18's activity. Similarly, PMA as a PKC activator and Ionomycin, through its calcium ionophore activity, might contribute to the activation of kinases or phosphatases that act on TTC18, leading to its enhanced activity. EGCG, by inhibiting certain protein kinases, and LY294002, as a PI3K inhibitor, could create a signaling environment that indirectly upregulates TTC18's functional role. U0126 and SB203580, both inhibitors of specific kinases within the MAPK pathway, might shift cellular signaling to favor TTC18 activation by reducing competing pathway activities.
Additionally, Sphingosine-1-phosphate serves as a signaling molecule that could activate G protein-coupled receptors, potentially influencing downstream kinases to enhance TTC18's activity. Thapsigargin may raise intracellular calcium levels, which in turn could activatecalcium-dependent pathways and indirectly enhance TTC18's functional activity. Okadaic acid, inhibiting protein phosphatases, could lead to sustained phosphorylation states of proteins, potentially including TTC18, thereby enhancing its activity. Staurosporine, although a broad-spectrum kinase inhibitor, could selectively activate TTC18 by inhibiting kinases that otherwise suppress its activity. Anisomycin, by activating stress-activated protein kinases like JNK, could also modulate signaling pathways in favor of TTC18's activation. Collectively, these diverse chemical compounds employ various mechanistic approaches to enhance the functional activity of TTC18, emphasizing the interconnectedness of cellular signaling pathways and their influence on the regulation of specific proteins such as TTC18.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin elevates intracellular cAMP levels, which can lead to the activation of PKA (protein kinase A). PKA is known to phosphorylate a multitude of proteins, potentially including TTC18, thereby enhancing TTC18's functional activity in its respective signaling pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in the regulation of various proteins. The activation of PKC can lead to downstream signaling events that enhance the activity of TTC18 through phosphorylation or other post-translational modifications. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. The rise in calcium may activate calcium-dependent kinases or phosphatases, which in turn could enhance the functional activity of TTC18 by modifying its phosphorylation state. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit certain protein kinases, which could lead to a reduction in competitive signaling pathways, potentially resulting in an indirect enhancement of TTC18's activity within its specific signaling niche. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter the PI3K/Akt pathway, which may have downstream effects on TTC18's activity, especially if TTC18 is influenced by Akt-mediated phosphorylation or protein interactions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By inhibiting this pathway, the signaling balance may shift in a way that enhances the activity of TTC18 if it is associated with MAPK signaling. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This bioactive lipid acts as a signaling molecule that can activate G protein-coupled receptors and downstream kinases, potentially leading to the enhancement of TTC18's activity through these signaling cascades. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), potentially leading to an increase in cytosolic calcium levels, which may indirectly enhance TTC18's activity through calcium-dependent signaling pathways. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is an inhibitor of protein phosphatases PP1 and PP2A, which may result in an increase in the phosphorylation levels of various proteins, hence potentially enhancing the activity of TTC18 by preventing its dephosphorylation. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Although staurosporine is a broad-spectrum kinase inhibitor, it may lead to the selective activation of certain pathways by blocking kinases that negatively regulate TTC18's activity. | ||||||